MedTrace Logo

Short Course of Miltefosine and Antimony to Treat Cutaneous Leishmaniasis in Bolivia

NCT00537953 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2007-10-02

No results posted yet for this study

Summary

The combination of a half-course of miltefosine and a half-course of antimony will be evaluated for efficacy and tolerance. The combination of miltefosine and antimony is chosen because these are now the two standard agents in Bolivia, and in vitro the combination was additive to mildly synergistic against a standard leishmania strain.

Conditions

  • Cutaneous Leihmaniasis

Interventions

DRUG

Miltefosine , meglumine antimoniate

Sponsors & Collaborators

  • Centro de Investigaciones Bioclínicas de la Fundación Fader

    lead OTHER

Principal Investigators

  • Jonathan Berman, MD, PhD · AB Foundation for Medical Research

  • Jorge Vargas, MD · Cenetrop

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Bolivia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00537953 on ClinicalTrials.gov